Lupin receives tentative approval from U.S. FDA for Valbenazine Capsules

Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA), Valbenazine Capsules, 40 mg, 60 mg, and 80 mg, to market a generic equivalent of Ingrezza® Capsules, 40 mg, 60 mg, and 80 mg, of Neurocrine Biosciences, Inc.

Valbenazine Capsules (RLD Ingrezza®) had estimated annual sales of USD 1,235 million in the U.S. (IQVIA MAT December 2022).

Shares of Lupin Limited was last trading in BSE at Rs. 639.75 as compared to the previous close of Rs. 648.50. The total number of shares traded during the day was 17205 in over 932 trades.

The stock hit an intraday high of Rs. 654.95 and intraday low of 638.55. The net turnover during the day was Rs. 11165870.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 USFDA TentativeApproval ANDA ValbenazineCapsules